ZB

Zura Bio Limited

ZURA·NASDAQ

$4.10

-5.9%
HealthcareBiotechnology

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.

At a Glance

Live Snapshot
Market Cap$266.59M
EPS-1.0600
P/E Ratio-4.97
Earnings Date08/13/2026

zura

Other Current Liabilities

Last Annual Value

12.41M

3-Year CAGR

65%

5-Year CAGR

115%

10-Year CAGR

47%

ZB

Zura Bio Limited Competitors Analysis of Other Current Liabilities

ZURA · NASDAQ
CompanyOther Current Liabilities
CAGR 3Y
CAGR 5Y
CAGR 10Y
ZURA logo
Zura Bio Limited
NASDAQ:ZURA
12.41M
117.8%114.7%N/A 
8.55M
15.3%21.5%N/A
16.54M
15.9%28.3%N/A
255.10K
-38.4%-11.2%N/A
3.52M
31.9%16.4%5.8%
17.68M
32.1%31.1%N/A
8.04M
463.1%N/AN/A
8.13M
27.9%22.8%N/A
8.56M
-2.6%9.7%N/A
3.71M
88.3%82.2%N/A
10.14M
106.9%9.5%N/A
ZB

Zura Bio Limited Fair Value Envelope

ZURA · NASDAQ

Our analysis suggests that ZURA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.1, this represents a potential HIDDEN relative to our calculated worth for Zura Bio Limited.

Intrinsic Value
Current Price: $4.1